A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
暂无分享,去创建一个
Arnold Munnich | Florent Barbault | A. Munnich | N. Kaci | C. Benoist-Lasselin | L. Legeai-Mallet | L. Le Corre | Y. Le Merrer | Aurélie Jonquoy | Emilie Mugniery | Catherine Benoist-Lasselin | Nabil Kaci | Laurent Le Corre | Anne-Lise Girard | Yves Le Merrer | Patricia Busca | Laurent Schibler | Laurence Legeai-Mallet | L. Schibler | F. Barbault | P. Busca | A. Girard | E. Mugniery | Aurélie Jonquoy | Y. Le Merrer*
[1] A. Munnich,et al. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia. , 2010, Bone.
[2] M. Laederich,et al. Achondroplasia: pathogenesis and implications for future treatment , 2010, Current opinion in pediatrics.
[3] François Radvanyi,et al. Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors. , 2010, Organic & biomolecular chemistry.
[4] S. Anai,et al. 1-tert-Butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a Selective Tyrosine Kinase Inhibitor of Fibroblast Growth Factor Receptor-3 (FGFR3), Inhibits Cell Proliferation of Bladder Cancer Carrying the FGFR3 Gene Mutation along with Up-Regu , 2010, Journal of Pharmacology and Experimental Therapeutics.
[5] William L Jorgensen,et al. Discovery of novel fibroblast growth factor receptor 1 kinase inhibitors by structure-based virtual screening. , 2010, Journal of medicinal chemistry.
[6] David D. McErlain,et al. The role of Akt1 in terminal stages of endochondral bone formation: angiogenesis and ossification. , 2009, Bone.
[7] A. Munnich,et al. New Insight on FGFR3-Related Chondrodysplasias Molecular Physiopathology Revealed by Human Chondrocyte Gene Expression Profiling , 2009, PloS one.
[8] C. Degnin,et al. FGFs in endochondral skeletal development , 2009, Trends in Endocrinology & Metabolism.
[9] Ruisheng Zhang,et al. Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2009, Bioorganic & medicinal chemistry.
[10] Kozo Nakamura,et al. C/EBPβ Promotes Transition from Proliferation to Hypertrophic Differentiation of Chondrocytes through Transactivation of p57Kip2 , 2009, PloS one.
[11] A. Munnich,et al. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. , 2009, Biochimica et biophysica acta.
[12] A. Kawanami,et al. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. , 2008, Human molecular genetics.
[13] N. Gray,et al. Targeting cancer with small molecule kinase inhibitors , 2009, Nature Reviews Cancer.
[14] François Maurel,et al. Cellular interaction through LewisX cluster: theoretical studies , 2008, Journal of molecular modeling.
[15] L. Thompson,et al. STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes , 2008, Journal of Cell Science.
[16] T. I. Morales,et al. Chondrocyte moves: clever strategies? , 2007, Osteoarthritis and cartilage.
[17] A. Munnich,et al. Human immortalized chondrocytes carrying heterozygous FGFR3 mutations: An in vitro model to study chondrodysplasias , 2007, FEBS letters.
[18] R. Baron,et al. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor , 2007, The FEBS journal.
[19] J. Pouysségur,et al. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition , 2007, Oncogene.
[20] L. Gibbs,et al. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. , 2007, Biochimica et biophysica acta.
[21] D. Ornitz,et al. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. , 2007, Developmental biology.
[22] H. E. Maclean,et al. The cyclin-dependent kinase inhibitor p57(Kip2) mediates proliferative actions of PTHrP in chondrocytes. , 2004, The Journal of clinical investigation.
[23] S. Murakami,et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. , 2004, Genes & development.
[24] Tomoko Iwata,et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. Munnich,et al. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. , 2004, Bone.
[26] E. Laplantine,et al. A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation , 2003, The Journal of cell biology.
[27] R. Adar,et al. FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation , 2002, FEBS letters.
[28] Andrea Vortkamp,et al. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. , 2002, Developmental cell.
[29] Christophe G. Lambert,et al. ESyPred3D: Prediction of proteins 3D structures , 2002, Bioinform..
[30] O. Rozenblatt-Rosen,et al. Induction of chondrocyte growth arrest by FGF: transcriptional and cytoskeletal alterations. , 2002, Journal of cell science.
[31] C. Lambert,et al. ESyPred 3 D : Prediction of proteins 3 D structures , 2002 .
[32] C. Albanese,et al. TGFbeta and PTHrP control chondrocyte proliferation by activating cyclin D1 expression. , 2001, Molecular biology of the cell.
[33] C. Deng,et al. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. , 2000, Human molecular genetics.
[34] F. Beier,et al. Cell cycle control in growth plate chondrocytes. , 2000, Frontiers in bioscience : a journal and virtual library.
[35] D. Givol,et al. Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice. , 2000, Human molecular genetics.
[36] R. Adar,et al. The Transmembrane Mutation G380R in Fibroblast Growth Factor Receptor 3 Uncouples Ligand-Mediated Receptor Activation from Down-Regulation , 2000, Molecular and Cellular Biology.
[37] S. Pol,et al. Delayed Union of Fractures, with Cases and Illustrations; the Successful Employment of Malgaigne’s Spike in Connection with Drilling, in a Case Which Had Previously Resisted Drilling Employed by Itself , 1863, Chicago medical examiner.
[38] C. Deng,et al. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. , 1999, Human molecular genetics.
[39] D. Ornitz,et al. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. , 1998, Development.
[40] A. Munnich,et al. Fibroblast Growth Factor Receptor 3 Mutations Promote Apoptosis but Do Not Alter Chondrocyte Proliferation in Thanatophoric Dysplasia* , 1998, The Journal of Biological Chemistry.
[41] David S. Goodsell,et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998, J. Comput. Chem..
[42] A. Munnich,et al. Abnormal FGFR 3 expression in cartilage of thanatophoric dysplasia fetuses. , 1997, Human molecular genetics.
[43] S. Elledge,et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith–Wiedemann syndrome , 1997, Nature.
[44] M. Barbacid,et al. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.
[45] Xin-Yuan Fu,et al. Activation of Statl by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism , 1997, Nature.
[46] John Kuriyan,et al. Structure of the C-Terminal Region of p21WAF1/CIP1 Complexed with Human PCNA , 1996, Cell.
[47] J. Weissenbach,et al. Clinical and genetic heterogeneity of hypochondroplasia. , 1996, Journal of medical genetics.
[48] Gary W. Harding,et al. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3 , 1996, Nature Genetics.
[49] A. Munnich,et al. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1). , 1996, Human molecular genetics.
[50] P. Leder,et al. Fibroblast Growth Factor Receptor 3 Is a Negative Regulator of Bone Growth , 1996, Cell.
[51] I. Kaitila,et al. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia , 1995, Nature Genetics.
[52] A. Munnich,et al. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1 , 1995, Nature Genetics.
[53] D. Rimoin,et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3 , 1995, Nature Genetics.
[54] T. Blankenship,et al. Developmental expression of Ki‐67 antigen and proliferating cell nuclear antigen in macaque placentas , 1994, Developmental dynamics : an official publication of the American Association of Anatomists.
[55] Arnold Munnich,et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia , 1994, Nature.
[56] D. Church,et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia , 1994, Cell.
[57] Hui Zhang,et al. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA , 1992, Cell.